Euvolemic Hyponatremia: Clinical Overview
Euvolemic hyponatremia is defined as hyponatremia (serum sodium <135 mmol/L) occurring in the setting of normal extracellular fluid volume—meaning no clinical evidence of volume depletion (no orthostasis, dry mucous membranes, decreased skin turgor) or volume overload (no edema, ascites, or jugular venous distension). 1, 2
Pathophysiology
Euvolemic hyponatremia results from water retention without proportional sodium retention, leading to dilutional hyponatremia despite normal total body sodium. The key mechanism is inappropriate antidiuretic hormone (ADH/vasopressin) activity that causes the kidneys to retain free water by increasing aquaporins in the collecting ducts, impairing free water clearance 1.
Diagnostic Criteria
The diagnosis requires a systematic biochemical approach, not just clinical assessment 1:
Essential Laboratory Findings:
- Serum sodium <135 mmol/L (some define as <134 mEq/L)
- Plasma osmolality <275 mOsm/kg (hypoosmolar)
- Urine osmolality >100 mOsm/kg (typically >300-500 mOsm/kg—inappropriately concentrated)
- Urine sodium >20-40 mEq/L (indicates adequate sodium intake and renal sodium handling)
- Serum uric acid <4 mg/dL (helpful confirmatory finding)
- Clinical euvolemia (normal volume status on examination)
Critical Exclusions Required:
You must rule out these conditions before confirming euvolemic hyponatremia 1:
- Hypothyroidism (check TSH)
- Adrenal insufficiency/hypocortisolism (check morning cortisol or ACTH stimulation test)
- Diuretic use (especially thiazides—check medication list)
- Heart failure, cirrhosis, nephrotic syndrome (these cause hypervolemic hyponatremia)
- Volume depletion (causes hypovolemic hyponatremia)
Most Common Cause: SIADH (Syndrome of Inappropriate Antidiuresis)
SIADH is the predominant cause of euvolemic hyponatremia in most clinical settings 3, 2, 4. The 2022 Korean Society of Nephrology guidelines emphasize that SIADH represents a state of persistent ADH elevation causing water retention 3.
Major Etiologies of SIADH 1, 5:
Malignancies:
- Small cell lung cancer (10-45% produce ADH, though only 1-5% symptomatic)
- Squamous cell carcinoma, adenocarcinoma (rare)
Pulmonary diseases:
- Pneumonia, tuberculosis, lung abscess
- Positive pressure ventilation
Central nervous system disorders:
- Meningitis, encephalitis, brain abscess
- Subarachnoid hemorrhage, subdural hematoma
- Stroke, traumatic brain injury
- Brain tumors
Medications (extremely common):
- Antidepressants (SSRIs, SNRIs, tricyclics)
- Antiepileptics (carbamazepine, oxcarbazepine, valproate)
- Antipsychotics
- Chemotherapy agents (cyclophosphamide, vincristine)
- NSAIDs, opioids
Clinical Significance and Symptoms
Even mild hyponatremia (130-135 mmol/L) carries clinical consequences 4, 3:
Symptom Severity by Sodium Level:
- 125-130 mEq/L: General weakness, confusion, headache, nausea
- <120 mEq/L: Life-threatening manifestations—seizures, coma, cardiorespiratory distress 1
- Chronic mild hyponatremia: Cognitive impairment, gait disturbances, increased falls (23.8% vs 16.4% in normonatremic patients), increased fractures (23.3% vs 17.3%), osteoporosis 4
The rapidity of development determines symptom severity more than the absolute sodium level—acute hyponatremia (<48 hours) causes more severe cerebral edema and symptoms than chronic hyponatremia (>48 hours) 2, 4.
Management Approach
For Asymptomatic or Mildly Symptomatic SIADH:
First-line treatment is fluid restriction to <1 L/day 1. However, the 2022 Korean guidelines acknowledge this is often ineffective in practice and primarily prevents further sodium decline rather than actively correcting it 3.
Second-line options 3:
- Oral sodium chloride tablets (1 g = 17 mEq sodium): 6-9 g daily in divided doses (2-3 g two to three times daily) combined with loop diuretics
- Loop diuretics (furosemide 20-40 mg once daily)—decrease medullary osmotic gradient, increase free water excretion
- Urea (0.25-0.50 g/kg daily or 600-1,200 mg)—increases solute load and free water excretion
For Moderate to Severe SIADH:
The 2022 Korean guidelines suggest vaptans (vasopressin V2-receptor antagonists) for moderate to severe hyponatremia in SIADH 3. Vaptans (tolvaptan 7.5-30 mg daily) effectively normalize sodium by causing selective free water excretion without sodium loss 3.
Important caveats about vaptans 3:
- Do not improve survival
- Risk of overcorrection (though not increased vs. placebo in trials)
- Potential hepatotoxicity (reported in polycystic kidney disease patients on high doses)
- Expensive
- Increase thirst
For Severely Symptomatic Hyponatremia (Medical Emergency):
Administer hypertonic 3% saline as rapid intermittent bolus to increase sodium by 4-6 mEq/L within 1-2 hours to reverse cerebral edema 3, 4. The 2022 Korean guidelines issued a conditional recommendation favoring rapid intermittent bolus over slow continuous infusion 3.
Critical correction limits to prevent osmotic demyelination syndrome (ODS) 3, 6, 4:
- Maximum 8-10 mEq/L increase in first 24 hours
- Maximum 18 mEq/L increase in 48 hours
- More stringent limit of <8 mEq/L per day for high-risk patients: sodium ≤105 mmol/L, hypokalemia, alcoholism, malnutrition, advanced liver disease
Monitor sodium every 1 hour after first hypertonic saline dose, then every 6 hours 3.
Critical Pitfall: Avoid 0.9% Normal Saline in SIADH
Normal saline acts paradoxically in SIADH patients—it can worsen hyponatremia because patients excrete the sodium while retaining the water due to high ADH levels 2. This creates dangerous rapid fluctuations: initial correction during infusion (risking ODS) followed by post-infusion worsening.
Differential Diagnoses to Consider
Cerebral salt wasting (CSW): Occurs in neurosurgical patients with subarachnoid hemorrhage or brain injury. Distinguished from SIADH by true volume depletion (though both have elevated urine sodium). Requires volume replacement, not restriction 7.
Reset osmostat: A variant where the osmostat is set at a lower level but water handling is otherwise normal. Patients maintain stable mild hyponatremia and don't require treatment 2.
Thiazide-induced hyponatremia: Can present as either hypovolemic or euvolemic (SIAD-like). The euvolemic subtype is more common and requires distinguishing from primary SIADH 8.
Workup Algorithm
- Confirm true hypotonic hyponatremia: Check serum osmolality (<275 mOsm/kg)
- Assess volume status clinically: Look specifically for orthostasis, skin turgor, mucous membranes, edema, ascites, JVD
- If euvolemic, obtain: Urine osmolality, urine sodium, serum uric acid
- Mandatory exclusions: TSH, morning cortisol, medication review for diuretics
- If SIADH confirmed, investigate cause: Chest imaging (CT preferred over X-ray), consider brain imaging if neurologic symptoms, review medications thoroughly 5
The fractional excretion of urate can improve diagnostic accuracy to 95% when assessing effective arterial blood volume 1.